Abstract

The clinical, angiographic and demographic characteristics of 42 patients with low-grade (<50%) residual stenosis at the infarct lesion after thrombolysis for acute myocardial infarction (MI) were assessed. The study group (group I) represented 21% of 198 consecutive patients receiving thrombolytic therapy over a 59-month period. Data on the 156 remaining patients were pooled for comparison (group II). Group I patients were predominantly men (86%) who were cigarette smokers (81%). Group II patients were predominantly men (75%, p > 0.10) but were significantly older (52 ± 12 vs 56 ± 10 years, p = 0.02). Prior acute MI or angina was unusual in group I. Sixty percent had no significant (>50%) residual coronary artery disease while 25% had residual single artery disease. Average significant (>50% diameter stenosis) residual vessel disease was 0.6 ± 1.0 for group I and 1.9 ± 0.9 for group II (p < 0.001). In group I, average residual infarct lesion diameter stenosis was 36 ± 7% in the right anterior oblique and 34 ± 8% in the left anterior oblique views. Thirty-nine group I patients were discharged with medical therapy and 100% follow-up was obtained over a mean interval of 18 ± 17 months. Fifteen patients experienced chest pain after acute MI accounting for 17 discrete events. Fifty-nine percent of group I had a benign course on follow-up. Eight events were classified as unstable angina, 4 as acute MI and 5 as atypical angina. Documented coronary vasospasm occurred in 3. The infarct narrowing accounted for 58% of documented ischemia and 41% of symptomatic events. Antiplatelet agents, warfarin and residual lesion morphology did not clearly influence frequency of events, whereas data regarding cigarette smoking were suggestive (p = 0.06). Events clearly associated with the infarct narrowing occurred earlier (4 ± 4 months) than events not related to (23 ± 15 months, p < 0.01). Ischemic events unrelated to the infarct lesion were often related to progressive stenosis or occlusion at the site of previously nonsignificant disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.